The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study

Objective: To assess the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) in treating clinical-T1N0M0 (cT1N0M0) papillary thyroid carcinoma (PTC) adjacent to the trachea. Methods: This study retrospectively analyzed 423 patients (563 cT1N0M0 PTC nodules) who underwent ultrasound-guided RFA at Xuanwu Hospital, Capital Medical University, between October 2020 and December 2023. All cases were confirmed as non-aggressive, without distant metastasis or concurrent malignancies, by RFA and imaging evidence. Based on the distance between the lesion and trachea (≤2 mm), the lesions were categorized into a trachea-adjacent group and a trachea-distant group. The study aimed to evaluate the efficacy and safety of RFA for cT1N0M0 PTC adjacent to the trachea. The rates of local recurrence, new lesions, lymph node metastasis (LNM), and complications are recorded and compared. Results: 1.Patient Distribution: The trachea-adjacent group included 102 cases (18.1%), while the trachea-distant group included 461 cases (81.9%). 2. There was no significant difference in the complete absorption rate and Disease-free survival rate (DFS) between the trachea-adjacent group and the trachea-distant group at different follow-up times (all p >0.05). 3. Disease Progression: Disease progression occurred in 10 patients (2.36%), including 8 cases of new lesions, 0 cases of residual lesions and 2 cases of LNM. The 8 new lesions happened at a mean detection time of (22.2 ± 1.1) months, with all underwent re-RFA, achieving complete absorption in all cases. After a mean follow-up of (37.6 ± 3.5) months, no additional new lesions or LNM were detected. There are no LNM in the trachea-adjacent group. 4. Comparative Outcomes Between Groups: No significant differences were observed between the trachea-adjacent and trachea-distant groups in terms of complete absorption rate, disease progression rate (all p > 0.05). 5. Complications and Risk Factors: Complications occurred in 15 patients (3.5%), with 11 cases in the trachea-adjacent group and 4 in the trachea-distant group, demonstrating a statistically significant difference ( p < 0.05). All complications occurred within 3 months post-RFA. Multivariate Logistic regression analysis identified tumor location in the thyroid dorsal region and the extent of tracheal contact as independent risk factors for complications. Conclusion: With precise preoperative evaluation, operative techniques and assessment, RFA is a relatively effective and safe treatment for cT1N0M0 PTC located adjacent to the trachea, providing patients with an additional therapeutic option.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-18
DOI
https://doi.org/10.1186/s12885-026-17372-6
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study

Xiaoxia Jia, Jingchun Yang, Leng Zhenpeng, Yifan Wang et al.
2 links
BMC Cancer
Thyroid Cancer Diagnosis and Treatment
article

The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study

Xiaoxia Jia, Jingchun Yang, Leng Zhenpeng, Yifan Wang, Ying Chang, Zimeng Lv, Xufen Yang
article en

Abstract

Objective: To assess the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) in treating clinical-T1N0M0 (cT1N0M0) papillary thyroid carcinoma (PTC) adjacent to the trachea. Methods: This study retrospectively analyzed 423 patients (563 cT1N0M0 PTC nodules) who underwent ultrasound-guided RFA at Xuanwu Hospital, Capital Medical University, between October 2020 and December 2023. All cases were confirmed as non-aggressive, without distant metastasis or concurrent malignancies, by RFA and imaging evidence. Based on the distance between the lesion and trachea (≤2 mm), the lesions were categorized into a trachea-adjacent group and a trachea-distant group. The study aimed to evaluate the efficacy and safety of RFA for cT1N0M0 PTC adjacent to the trachea. The rates of local recurrence, new lesions, lymph node metastasis (LNM), and complications are recorded and compared. Results: 1.Patient Distribution: The trachea-adjacent group included 102 cases (18.1%), while the trachea-distant group included 461 cases (81.9%). 2. There was no significant difference in the complete absorption rate and Disease-free survival rate (DFS) between the trachea-adjacent group and the trachea-distant group at different follow-up times (all p >0.05). 3. Disease Progression: Disease progression occurred in 10 patients (2.36%), including 8 cases of new lesions, 0 cases of residual lesions and 2 cases of LNM. The 8 new lesions happened at a mean detection time of (22.2 ± 1.1) months, with all underwent re-RFA, achieving complete absorption in all cases. After a mean follow-up of (37.6 ± 3.5) months, no additional new lesions or LNM were detected. There are no LNM in the trachea-adjacent group. 4. Comparative Outcomes Between Groups: No significant differences were observed between the trachea-adjacent and trachea-distant groups in terms of complete absorption rate, disease progression rate (all p > 0.05). 5. Complications and Risk Factors: Complications occurred in 15 patients (3.5%), with 11 cases in the trachea-adjacent group and 4 in the trachea-distant group, demonstrating a statistically significant difference ( p < 0.05). All complications occurred within 3 months post-RFA. Multivariate Logistic regression analysis identified tumor location in the thyroid dorsal region and the extent of tracheal contact as independent risk factors for complications. Conclusion: With precise preoperative evaluation, operative techniques and assessment, RFA is a relatively effective and safe treatment for cT1N0M0 PTC located adjacent to the trachea, providing patients with an additional therapeutic option.

BMC Cancer
Capital Medical University (CN), Xuan Wu Hospital of the Capital Medical University (CN)
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon